IP Library Granted Patent US 10,016,455
Granted Patent B2
US 10,016,455 · App. 15/590,284 · Granted Jul 10, 2018

Method of preventing or treating influenza with oxidative reductive potential water solution

Inventor: Hojabr Alimi (Santa Rosa, CA)
Assignee: Sonoma Pharmaceuticals, Inc.
A61K33/20A61K9/007A61K9/0019A61K33/40A61K45/06A61K47/32A61L2/0088A61L2/035A61L2/186C02F1/4618C02F1/4672
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,016,455
App. No.
15/590,284
Granted
Jul 10, 2018
Kind
B2
Abstract

Provided is a method for preventing or treating influenza by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers. The ORP water solution can be administered alone or, e.g., in combination with one or more additional therapeutic agents.

Claims (5)

1. A method of treating or preventing a viral infection in a patient comprising administering a therapeutically effective amount of an oxidative reductive potential water solution to an infectious virus present on a surface of a tissue, wherein the infectious virus is an influenza virus, wherein the solution comprises about 10 ppm to about 400 ppm of free chlorine species selected from hypochlorous acid, hypochlorite ions, sodium hypochlorite, chlorite ions, chloride ion, chlorine dioxide, dissolved chlorine gas, and mixtures thereof, wherein the solution comprises a mixture of anode water and cathode water, the pH of the ORP water solution is between about 6.2 and about 7.8, and wherein the solution is stable for at least two months, wherein the solution is administered by aerosolization, nebulization and atomization.

2. The method of claim 1 , wherein the influenza virus is an influenza A virus.

3. The method of claim 1 , wherein the solution comprises about 50 ppm to about 200 ppm of free chlorine species.

4. The method of claim 3 , wherein the free chlorine species comprises from about 15 ppm to about 35 ppm of hypochlorous acid and from about 25 ppm to about 50 ppm of sodium hypochlorite.

5. The method of claim 1 , wherein the solution comprises from about 10% by volume to about 50% by volume of cathode water and from about 50% by volume to about 90% by volume of anode water.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2017
From: ALIMI, HOJABR
To: OCULUS INNOVATIVE SCIENCES, INC.
Reel/Frame 042307/0980 →
CHANGE OF NAME Recorded May 9, 2017
From: OCULUS INNOVATIVE SCIENCES, INC.
To: SONOMA PHARMACEUTICALS, INC.
Reel/Frame 042432/0512 →
Continuity (5)
Division 14924361 · Oct 27, 2015
Continuation 10916566 · Aug 11, 2004
Continuation In Part 10862092 · Jun 4, 2004
Provisional Application 60533583 · Dec 30, 2003
Related Publication 20170239291A1 · Aug 24, 2017
Cited By (1)
US 12,419,909